GeneralConnection.com ➔ Dictionary
Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
Speaking with the man, first in Canada, to receive breakthrough hemophilia B gene therapy - CP24
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada - Yahoo! Finance Canada
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Explainer: Why Is Hemophilia B Called Christmas Disease? - Global Biotechnology Company
Karmanos Cancer Institute Becomes First and Only Free-Standing Cancer Center to Treat Hemophilia B with New Gene Therapy - McLaren Health
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
Growth of Recombinant Human Coagulation Factor IX Market, - openPR.com
Gene Therapy Supply Runs Out, Company Warns of Treatment Delays - MedPage Today
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting - Biogen
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen - Frontiers
Pfizer receives EC approval for Hympavzi to treat haemophilia - Yahoo
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
How durable is gene therapy for haemophilia B? - Nature
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years - MedPage Today
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
One dose of gene therapy gives years of relief from blood disorder - Nature
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade - Managed Healthcare Executive
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - The New England Journal of Medicine
Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later - MedPage Today
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Systemic delivery of factor IX messenger RNA for protein replacement therapy - PNAS
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - The New England Journal of Medicine
Plasma factor IX: The tip of the iceberg? - Sidonio - 2021 - Haemophilia - Wiley Online Library
Vitamin K-dependent carboxylation of coagulation factors: insights from a cell-based functional study - Haematologica
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Etranacogene Dezaparvovec Displays Superiority to Factor IX Prophylaxis for Hemophilia B in HOPE-B Trial Data - CGTLive®
Field Study Highlights Differences in Factor IX Variant Lab Results - The American Journal of Managed Care® (AJMC®)
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
CDC Hemophilia Mutation Projects (CHAMP and CHBMP) - Centers for Disease Control and Prevention | CDC (.gov)
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
Haemophilia gene therapy patients thriving over a decade after treatment | UCL News - UCL - UCL | University College London
A coagulation factor moonlights in the heart - Science | AAAS
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
Factor IX Deficiency and Prolonged Bleeding Time - The New England Journal of Medicine
Hemophilia B Durham: A Mutation in the First EGF-Like Domain of Factor IX That Is Characterized by Polymerase Chain Reaction - ScienceDirect.com
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia - Hematology Advisor
Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B - 2 Minute Medicine
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B - UC San Diego Health
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials Online
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - The New England Journal of Medicine
Gene therapy fails to induce sustained factor IX activity for patients with hemophilia B - Healio
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients - 2 Minute Medicine
Krüppel-like factor 9 alleviates Alzheimer’s disease via IDE-mediated Aβ degradation - Nature
St. Jude's contribution to two new durable 'one-time' hemophilia drugs - St. Jude Children's Research Hospital
Hemophilia B Gene Therapy Shows Promise as Long-Term Treatment - Docwire News
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B - 2 Minute Medicine
Evaluation of a New Concentrate for the Treatment of Factor IX Deficiency - The New England Journal of Medicine
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - The American Journal of Managed Care® (AJMC®)
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
The Experience Factor: 9 activations which lit up summer travel retail - DFNI
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
Personal Story: Carrie - Centers for Disease Control and Prevention | CDC (.gov)
Pulmonary Hemorrhage: An Unusual Life-Threatening Presentation of Factor IX Deficiency in a Monochorionic-Diamniotic Twin Neonate - Cureus
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector - Nature
Effective Blood Clotting Treatment:Pharmacogenomic Studies of ADAMTS13 - fda.gov
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors - The New England Journal of Medicine
Hemophilia Gene Therapies Show Effectiveness and Safety in NEJM Reports - Inside Precision Medicine
Is Hemophilia a Nosologic Entity? - ScienceDirect.com
Interferon Regulatory Factor 9 Structure and Regulation - Frontiers
Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
A genetic analysis of 23 Chinese patients with hemophilia B - Nature
Hemophilia therapy: the future has begun - Haematologica
Factor IX product launched in US - MDEdge
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma - Nature
FDA Approves Second Gene Therapy for Hemophilia B - Medscape
Hemophilia B Gene Therapy Shows Promise in Clinical Trial - Genetic Engineering and Biotechnology News
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond - The Lancet
Researchers welcome $3.5-million haemophilia gene therapy — but questions remain - Nature
uniQure announces FDA approval of first gene therapy for adults with hemophilia B - uniqure.gcs-web.com
New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use - Biogen
Loss of Krüppel-like factor 9 deregulates both physiological gene expression and development - Nature
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
facor ix,   factor iix,   factr ix,   facyor ix,   faxtor ix,   factoor ix,   faactor ix,   factor xi,   fatcor ix,   factor ox,   favtor ix,   ffactor ix,   facctor ix,   facror ix,   factor iz,   factot ix,   fsctor ix,   factpr ix,   facter ix,   facttor ix,   factor x,   dactor ix,   facto rix,   factor ixx,   factor ix,   fcator ix,   fator ix,   factori x,   afctor ix,   fctor ix,   factoe ix,   actor ix,   factor ic,   factorr ix,   factir ix,   facotr ix,   factro ix,   gactor ix,   factor i,   facto ix,   factorix,   factor ux
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z